Latest papers

E-cigarettes: a rapidly growing Internet phenomenon.

Ketoprofen gels: unfortunately back on the French market.

Medical marijuana. A smoking-hot business opportunity?

Benfluorex: EU marketing authorisation finally withdrawn.

[Fighting with the Danish Medical Agency--core activity of the medical profession?].

Sex, gender, and pharmaceutical politics: From drug development to marketing.

The marketing of dietary supplements in North America: the emperor is (almost) naked.

The nocebo effect: a reason for patients' non-adherence to generic substitution?

Electronic prescriptions for controlled substances.

[The evolution of pharmaceutical practice within the context of changing health territories: How can social sciences contribute to pharmaceutical education?].

Pharmacovigilance: an opportunity for the European Commission to put patients' interests first.

Payers begin to make plans for coming wave of biosimilars.

B.C. Court of Appeal upholds supervised injection site's right to operate.

Fake botox, real threat.

[Non-interventional post-authorisation studies in Spain: justification and basis of a new regulation].

Rule oks E-scripts for controlled Rx.

Regulation of biomedical products.

Regulation of vitamin and mineral supplements: lessons from the Truehope saga.

Medicare part D's exclusion of benzodiazepines and fracture risk in nursing homes.

Medical marijuana and the law.